|
Market Closed -
Australian S.E.
09:10:18 02/09/2026 +03
|
5-day change | 1st Jan Change | ||
| 8.360 AUD | +1.46% |
|
-21.13% | -32.91% |
| 08-28 | Morgans Financial Downgrades Clinuvel Pharmaceuticals to Hold from Speculative Buy; Price Target is AU$10 | MT |
| 08-27 | Clinuvel Pharmaceuticals Limited, 2026 Earnings Call, Aug 27, 2026 |
| Market Cap | 422M 302M 261M 246M 224M 418M 28.56B 2.91B 1.13B 14.6B 1.14B 1.11B 47.97B | P/E 2027 * |
11.8x | P/E 2028 * | 11.1x |
|---|---|---|---|---|---|
| Enterprise Value | 138M 98.74M 85.18M 80.24M 73.11M 137M 9.33B 950M 369M 4.77B 371M 363M 15.67B | EV / Sales 2027 * |
1.45x | EV / Sales 2028 * | 1.01x |
| Free-Float |
83.79% | Yield 2027 * |
0.65% | Yield 2028 * | 0.78% |
Last Transcript : Clinuvel Pharmaceuticals Limited
| 1 day | +1.46% | ||
| 1 week | -21.13% | ||
| Current month | +4.24% | ||
| 1 month | -7.73% | ||
| 3 months | -9.72% | ||
| 6 months | -16.48% | ||
| Current year | -32.91% |
| 1 week | 8.01 |  | 10.85 |
| 1 month | 8.01 | | 11.13 |
| Current year | 8.01 | | 13.48 |
| 1 year | 8.01 | | 13.48 |
| 3 years | 8.01 | | 18.44 |
| 5 years | 8.01 | | 44.67 |
| 10 years | 5.04 | | 45.88 |
| Manager | Title | Age | Since |
|---|---|---|---|
Philippe Wolgen
CEO | Chief Executive Officer | 63 | 01/11/2005 |
Peter Vaughan
DFI | Director of Finance/CFO | 42 | 30/06/2024 |
| Chief Tech/Sci/R&D Officer | - | - |
| Director | Title | Age | Since |
|---|---|---|---|
Karen Agersborg
BRD | Director/Board Member | - | 29/01/2018 |
Susan Smith
BRD | Director/Board Member | - | 23/09/2019 |
| Chairman | - | 01/01/2024 |
| Date | Insider | Type | Main position | Quantity | % Market Cap. | Importance |
|---|---|---|---|---|---|---|
| 10/3/24 A | Buy | Director | 8,333 | 0.0166% | ||
| 11/27/23 A | Exercice | Chief Executive Officer | 301,125 | 0.6094% | ||
| 11/27/23 A | Expiration | Chief Executive Officer | 1,513,750 | 3.0636% |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | +1.46% | -21.13% | -22.01% | -54.52% | 297M | |
| +3.42% | +4.57% | +47.44% | +3.54% | 82.26B | |
| -2.24% | +0.77% | +523.44% | +37.90% | 61.59B | |
| +0.89% | +0.12% | -17.32% | -35.39% | 59.05B | |
| -1.25% | -5.30% | -1.98% | +33.18% | 51.23B | |
| +0.92% | -1.61% | +10.69% | +165.47% | 48.3B | |
| +3.07% | +0.72% | +59.47% | -16.38% | 31.92B | |
| +3.06% | +0.55% | +49.84% | +103.59% | 25.34B | |
| +0.20% | +1.70% | -3.42% | +190.03% | 22.56B | |
| -0.52% | -3.11% | +60.78% | +115.64% | 16.56B | |
| Average | +0.88% | -4.47% | +70.69% | +54.31% | 39.91B | |
| Weighted average by Cap. | +0.84% | -2.79% | +99.27% | +46.39% |
| 2027 * | 2028 * | |
|---|---|---|
| Net sales | 94.86M 68.03M 58.69M 55.29M 50.37M 94.16M 6.43B 655M 254M 3.29B 255M 250M 10.79B | 103M 73.89M 63.74M 60.05M 54.71M 102M 6.98B 711M 276M 3.57B 277M 271M 11.72B |
| Net income | 36.02M 25.83M 22.28M 20.99M 19.13M 35.75M 2.44B 249M 96.45M 1.25B 96.99M 94.87M 4.1B | 38.1M 27.32M 23.57M 22.21M 20.23M 37.82M 2.58B 263M 102M 1.32B 103M 100M 4.33B |
| Net Debt | -284M -204M -176M -165M -151M -282M -19.23B -1.96B -760M -9.83B -765M -748M -32.3B | -317M -228M -196M -185M -168M -315M -21.5B -2.19B -850M -10.99B -854M -836M -36.1B |
| Date | Price | Change | Volume |
|---|---|---|---|
| 02/09/26 | A$8.360 | +1.46% | 187,737 |
| 01/09/26 | A$8.240 | +2.74% | 252,968 |
| 31/08/26 | A$8.020 | -5.31% | 332,582 |
| 28/08/26 | A$8.470 | -7.73% | 571,697 |
| 27/08/26 | A$9.180 | -12.74% | 481,909 |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Quarterly revenue - Rate of surprise
- Stock Market
- Stocks
- CUV Stock
Select your edition
All financial news and data tailored to specific country editions
